Regional atrophy associated with cognitive and motor function in prodromal huntington disease

The PREDICT-HD Investigators and Coordinators of the Huntington Study Group, Kimberly Quaid

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Neuroimaging studies suggest that volumetric MRI measures of specific brain structures may serve as excellent biomarkers in future clinical trials of Huntington disease (HD). Objective: Demonstration of the clinical significance of these measures is an important step in determining their appropriateness as potential outcome measures. Methods: Measures of gray- and white-matter lobular volumes and subcortical volumes (caudate, putamen, globus pallidus, thalamus, nucleus accumbens, hippocampus) were obtained from MRI scans of 516 individuals who tested positive for the HD gene expansion, but were not yet exhibiting signs or symptoms severe enough to warrant diagnosis ("pre-HD"). MRI volumes (corrected for intracranial volume) were correlated with cognitive, motor, psychiatric, and functional measures known to be sensitive to subtle changes in pre-HD. Results: Caudate, putamen, and globus pallidus volumes consistently correlated with cognitive and motor, but not psychiatric or functional measures in pre-HD. Volumes of white matter, nucleus accumbens, and thalamus, but not cortical gray matter, also correlated with some of the motor and cognitive measures. Conclusions: Results of regression analyses suggest that volumes of basal ganglia structures contributed more highly to the prediction of most motor and cognitive variables than volumes of other brain regions. These results support the use of volumetric measures, especially of the basal ganglia, as outcome measures in future clinical trials in pre-HD. Results may also assist investigators in selecting the most appropriate measures for treatment trials that target specific clinical features or regions of neuropathology.

Original languageEnglish (US)
Pages (from-to)477-489
Number of pages13
JournalJournal of Huntington's disease
Volume2
Issue number4
DOIs
StatePublished - 2013

Fingerprint

Huntington Disease
Cognition
Atrophy
Globus Pallidus
Putamen
Nucleus Accumbens
Basal Ganglia
Thalamus
Psychiatry
Outcome Assessment (Health Care)
Clinical Trials
Brain
Neuroimaging
Signs and Symptoms
Hippocampus
Biomarkers
Regression Analysis
Research Personnel
Magnetic Resonance Imaging
Genes

Keywords

  • Cognitive
  • Huntington disease
  • Magnetic resonance imaging
  • Motor
  • Psychiatric

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

The PREDICT-HD Investigators and Coordinators of the Huntington Study Group, & Quaid, K. (2013). Regional atrophy associated with cognitive and motor function in prodromal huntington disease. Journal of Huntington's disease, 2(4), 477-489. https://doi.org/10.3233/JHD-130076

Regional atrophy associated with cognitive and motor function in prodromal huntington disease. / The PREDICT-HD Investigators and Coordinators of the Huntington Study Group; Quaid, Kimberly.

In: Journal of Huntington's disease, Vol. 2, No. 4, 2013, p. 477-489.

Research output: Contribution to journalArticle

The PREDICT-HD Investigators and Coordinators of the Huntington Study Group & Quaid, K 2013, 'Regional atrophy associated with cognitive and motor function in prodromal huntington disease', Journal of Huntington's disease, vol. 2, no. 4, pp. 477-489. https://doi.org/10.3233/JHD-130076
The PREDICT-HD Investigators and Coordinators of the Huntington Study Group, Quaid K. Regional atrophy associated with cognitive and motor function in prodromal huntington disease. Journal of Huntington's disease. 2013;2(4):477-489. https://doi.org/10.3233/JHD-130076
The PREDICT-HD Investigators and Coordinators of the Huntington Study Group ; Quaid, Kimberly. / Regional atrophy associated with cognitive and motor function in prodromal huntington disease. In: Journal of Huntington's disease. 2013 ; Vol. 2, No. 4. pp. 477-489.
@article{abf9b54a28c14bb38b574205c1b1d6f3,
title = "Regional atrophy associated with cognitive and motor function in prodromal huntington disease",
abstract = "Background: Neuroimaging studies suggest that volumetric MRI measures of specific brain structures may serve as excellent biomarkers in future clinical trials of Huntington disease (HD). Objective: Demonstration of the clinical significance of these measures is an important step in determining their appropriateness as potential outcome measures. Methods: Measures of gray- and white-matter lobular volumes and subcortical volumes (caudate, putamen, globus pallidus, thalamus, nucleus accumbens, hippocampus) were obtained from MRI scans of 516 individuals who tested positive for the HD gene expansion, but were not yet exhibiting signs or symptoms severe enough to warrant diagnosis ({"}pre-HD{"}). MRI volumes (corrected for intracranial volume) were correlated with cognitive, motor, psychiatric, and functional measures known to be sensitive to subtle changes in pre-HD. Results: Caudate, putamen, and globus pallidus volumes consistently correlated with cognitive and motor, but not psychiatric or functional measures in pre-HD. Volumes of white matter, nucleus accumbens, and thalamus, but not cortical gray matter, also correlated with some of the motor and cognitive measures. Conclusions: Results of regression analyses suggest that volumes of basal ganglia structures contributed more highly to the prediction of most motor and cognitive variables than volumes of other brain regions. These results support the use of volumetric measures, especially of the basal ganglia, as outcome measures in future clinical trials in pre-HD. Results may also assist investigators in selecting the most appropriate measures for treatment trials that target specific clinical features or regions of neuropathology.",
keywords = "Cognitive, Huntington disease, Magnetic resonance imaging, Motor, Psychiatric",
author = "{The PREDICT-HD Investigators and Coordinators of the Huntington Study Group} and Aylward, {Elizabeth H.} and Harrington, {Deborah L.} and Mills, {James A.} and Nopoulos, {Peggy C.} and Ross, {Christopher A.} and Long, {Jeffrey D.} and Dawei Liu and Westervelt, {Holly K.} and Paulsen, {Jane S.} and Stephen Cross and Patricia Ryan and Epping, {Eric A.} and Edmond Chiu and Joy Preston and Anita Goh and Stephanie Antonopoulos and Samantha Loi and Lynn Raymond and Joji Decolongon and Mannie Fan and Allison Coleman and Mallonee, {William M.} and Greg Suter and Mark Varvaris and Nadine Yoritomo and Elizabeth McCusker and Jane Griffith and Clement Loy and David Gunn and Mark Guttman and Alanna Sheinberg and Kimberly Quaid and Kimberly Quaid and Melissa Wesson and Joanne Wojcieszek and Joel Perlmutter and Stacey Barton and Shineeka Smith and Barker, {Roger A.} and Sarah Mason and Guzman, {Natalie Valle} and Susan Perlman and Brian Clemente and Randi Jones and Cathy Wood-Siverio and Factor, {Stewart A.} and Ali Samii and Alma Macaraeg and Peter Panegyres and Ying Zhang",
year = "2013",
doi = "10.3233/JHD-130076",
language = "English (US)",
volume = "2",
pages = "477--489",
journal = "Journal of Huntington's disease",
issn = "1879-6397",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Regional atrophy associated with cognitive and motor function in prodromal huntington disease

AU - The PREDICT-HD Investigators and Coordinators of the Huntington Study Group

AU - Aylward, Elizabeth H.

AU - Harrington, Deborah L.

AU - Mills, James A.

AU - Nopoulos, Peggy C.

AU - Ross, Christopher A.

AU - Long, Jeffrey D.

AU - Liu, Dawei

AU - Westervelt, Holly K.

AU - Paulsen, Jane S.

AU - Cross, Stephen

AU - Ryan, Patricia

AU - Epping, Eric A.

AU - Chiu, Edmond

AU - Preston, Joy

AU - Goh, Anita

AU - Antonopoulos, Stephanie

AU - Loi, Samantha

AU - Raymond, Lynn

AU - Decolongon, Joji

AU - Fan, Mannie

AU - Coleman, Allison

AU - Mallonee, William M.

AU - Suter, Greg

AU - Varvaris, Mark

AU - Yoritomo, Nadine

AU - McCusker, Elizabeth

AU - Griffith, Jane

AU - Loy, Clement

AU - Gunn, David

AU - Guttman, Mark

AU - Sheinberg, Alanna

AU - Quaid, Kimberly

AU - Quaid, Kimberly

AU - Wesson, Melissa

AU - Wojcieszek, Joanne

AU - Perlmutter, Joel

AU - Barton, Stacey

AU - Smith, Shineeka

AU - Barker, Roger A.

AU - Mason, Sarah

AU - Guzman, Natalie Valle

AU - Perlman, Susan

AU - Clemente, Brian

AU - Jones, Randi

AU - Wood-Siverio, Cathy

AU - Factor, Stewart A.

AU - Samii, Ali

AU - Macaraeg, Alma

AU - Panegyres, Peter

AU - Zhang, Ying

PY - 2013

Y1 - 2013

N2 - Background: Neuroimaging studies suggest that volumetric MRI measures of specific brain structures may serve as excellent biomarkers in future clinical trials of Huntington disease (HD). Objective: Demonstration of the clinical significance of these measures is an important step in determining their appropriateness as potential outcome measures. Methods: Measures of gray- and white-matter lobular volumes and subcortical volumes (caudate, putamen, globus pallidus, thalamus, nucleus accumbens, hippocampus) were obtained from MRI scans of 516 individuals who tested positive for the HD gene expansion, but were not yet exhibiting signs or symptoms severe enough to warrant diagnosis ("pre-HD"). MRI volumes (corrected for intracranial volume) were correlated with cognitive, motor, psychiatric, and functional measures known to be sensitive to subtle changes in pre-HD. Results: Caudate, putamen, and globus pallidus volumes consistently correlated with cognitive and motor, but not psychiatric or functional measures in pre-HD. Volumes of white matter, nucleus accumbens, and thalamus, but not cortical gray matter, also correlated with some of the motor and cognitive measures. Conclusions: Results of regression analyses suggest that volumes of basal ganglia structures contributed more highly to the prediction of most motor and cognitive variables than volumes of other brain regions. These results support the use of volumetric measures, especially of the basal ganglia, as outcome measures in future clinical trials in pre-HD. Results may also assist investigators in selecting the most appropriate measures for treatment trials that target specific clinical features or regions of neuropathology.

AB - Background: Neuroimaging studies suggest that volumetric MRI measures of specific brain structures may serve as excellent biomarkers in future clinical trials of Huntington disease (HD). Objective: Demonstration of the clinical significance of these measures is an important step in determining their appropriateness as potential outcome measures. Methods: Measures of gray- and white-matter lobular volumes and subcortical volumes (caudate, putamen, globus pallidus, thalamus, nucleus accumbens, hippocampus) were obtained from MRI scans of 516 individuals who tested positive for the HD gene expansion, but were not yet exhibiting signs or symptoms severe enough to warrant diagnosis ("pre-HD"). MRI volumes (corrected for intracranial volume) were correlated with cognitive, motor, psychiatric, and functional measures known to be sensitive to subtle changes in pre-HD. Results: Caudate, putamen, and globus pallidus volumes consistently correlated with cognitive and motor, but not psychiatric or functional measures in pre-HD. Volumes of white matter, nucleus accumbens, and thalamus, but not cortical gray matter, also correlated with some of the motor and cognitive measures. Conclusions: Results of regression analyses suggest that volumes of basal ganglia structures contributed more highly to the prediction of most motor and cognitive variables than volumes of other brain regions. These results support the use of volumetric measures, especially of the basal ganglia, as outcome measures in future clinical trials in pre-HD. Results may also assist investigators in selecting the most appropriate measures for treatment trials that target specific clinical features or regions of neuropathology.

KW - Cognitive

KW - Huntington disease

KW - Magnetic resonance imaging

KW - Motor

KW - Psychiatric

UR - http://www.scopus.com/inward/record.url?scp=84906929865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906929865&partnerID=8YFLogxK

U2 - 10.3233/JHD-130076

DO - 10.3233/JHD-130076

M3 - Article

VL - 2

SP - 477

EP - 489

JO - Journal of Huntington's disease

JF - Journal of Huntington's disease

SN - 1879-6397

IS - 4

ER -